Will Eli Lilly's new weight loss drug Zepbound sell >$2B in the US by 2025? (first full year on the market)
5
Ṁ110Ṁ1.2kresolved Feb 16
Resolved
YES1H
6H
1D
1W
1M
ALL
This market will resolve to YES if Zepbound has sold at least $2 billion in the US after its first 4 full quarters on the market. The evaluation criteria will be Eli Lilly's Annual Report for FY 2024. This is expected to be available in February 2025.
This question is managed and resolved by Manifold.
Market context
Get 
1,000 to start trading!
1,000🏅 Top traders
| # | Trader | Total profit |
|---|---|---|
| 1 | Ṁ67 | |
| 2 | Ṁ10 | |
| 3 | Ṁ5 | |
| 4 | Ṁ2 | |
| 5 | Ṁ1 |
People are also trading
Related questions
Will Eli Lilly’s reported Q1 2026 tirzepatide sales (Zepbound/Mounjaro) show >50% YoY growth?
67% chance
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Affordable weight loss drugs before 2030?
73% chance
Will a large insurance company cover weight loss drugs before 2027?
91% chance
Will Retatrutide (new obesity drug) be FDA approved by the end of 2026?
41% chance
More than 30% of US citizens will be on prescription drugs for weight loss by 2031
22% chance
Will a majority government owned company introduce a new GLP-1 drug before 2040?
15% chance
More than 10% of US citizens will be on prescription drugs for weight loss by 2031
71% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
86% chance
Will Medicare or Medicaid cover weight loss drugs by 2029?
79% chance